LFVN News & Events

Backs FY26 revenue view $185M-$200M, consensus $192.75M. Backs FY26 adjusted EBITDA view $15M-$19M. The company said, "The Company anticipates fiscal 2026 revenue, adjusted EBITDA, and adjusted earnings per share to be close to the lower end of our previously issued guidance range. The Company expects a full year tax rate of approximately 18% to 20%. This guidance reflects the current trends in the business and the Company's strategic initiatives, including international expansion and new product launches. The Company's guidance for adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per diluted share excludes any non-operating or non-recurring expenses that may materialize during fiscal 2026."

Reports Q3 revenue $43.72M, consensus $47.77M. "Third quarter results were softer than we anticipated as lower sales of our MindBody GLP-1 System were only partially offset by the addition of LoveBiome," said Michael Beindorff, Interim CEO of LifeVantage. "Despite top-line headwinds, we remained focused on managing expenses and allocating capital, enabling us to continue repurchasing shares while maintaining a strong balance sheet and cash position. That said, we are not satisfied with our performance and are laser focused on making the changes necessary to improve results going forward. With our science-backed approach to nutrigenomics, diversified product portfolio, passionate consultant community, and strong financial foundation, LifeVantage is in a compelling position in the rapidly expanding health and wellness market with significant growth potential ahead, and we intend to realize that potential."

LifeVantage Corporation announced it has been granted a United States Patent No. 12,589,067 B2, issued March 31, 2026, for nutritional supplement composition and methods for activating cellular signaling genes of its Healthy Glow Essentials Stack which contains key activators Protandim Nrf2 Synergizer and TrueScienceLiquid Collagen.